These data suggest that promoting TRAF3 or targeting NF-κB p100 processing to prevent TNF-induced NF-κB p100 accumulation may represent novel therapeutic strategies to treat inflammatory bone resorption associated with RA, periodontitis, or periprosthetic osteolysis. Here, TNF is linked to rheumatoid arthritis.